Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenal Suppression and PK of 188-0551 Spray vs RLD in Plaque Psoriasis
NCT04080206Phase 2Completed
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Halobetasol propionate 0.05% lotion in plaque psoriasis (2 arms). Primary endpoint: Proportion of subjects to exhibit adrenal suppression as measured by a cortrosyn stimulation test at Day 15. Started Apr 2020; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotion
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04080206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080206.